spacer
home > epc > autumn 2003 > pharmacogenomics and the impact on central laboratories
PUBLICATIONS
European Pharmaceutical Contractor

Pharmacogenomics and the Impact on Central Laboratories

Fifty years on from the discovery of DNA's double-helical structure, James Watson and Francis Crick's claim that they had “found the secret of life' has been complemented nicely by the completion of the Human Genome Project in April 2003. The Human Genome Project began in 1990 at a time when scientists had discovered fewer than 100 disease genes. Today, more than 99 per cent of the human genome has been sequenced and over 1,400 disease genes have been identified.

Human Genome Project and Drug Development

For the drug development industry, the consequences of sequencing the human genome have not yet been fully realised. Increasingly however, over the past number of years, in order to take advantage of the information gained in the Human Genome Project, pharmaceutical and biotechnology companies are seeking to incorporate pharmacogenomic components into their clinical protocols. The term pharmacogenomics is derived from the words pharmacology and genomics, and the discipline itself is a combination of those two sciences. In relation to drug development, pharmacogenomics is concerned with the study of how an individual's genetic inheritance affects the body's response to drugs.

Pharmacogenomics holds the promise that drugs can be developed which are targeted at a specific population, improving drug safety and efficacy, unlike the current practice for drug development whereby ‘one size fits all'. This current practice has proven very successful for pharmaceutical companies and many have profited significantly from a number of blockbuster drugs. However, with productivity of pharmaceutical research and development affecting revenue growth and investor confidence, many pharmaceutical companies are now examining other options for drug development, and in this regard one key area of interest is pharmacogenomics.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Michelle Lynskey, Business Development Analyst at ICON Laboratories, Europe

Michelle Lynskey is Business Development Analyst at ICON Laboratories, Europe. She holds a Degree in Biotechnology from the National University of Ireland, Galway, and a Masters in Science Communication from Dublin City University and Queen's University Belfast. Prior to joining ICON Laboratories in 2002, Michelle worked as a Biochemist in Immunology R&D for Olympus Diagnostica and as a Technologies Analyst in drug delivery for Elan Corporation.

spacer
Michelle Lynskey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinsonís disease treatment

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
More info >>

White Papers

Preparation of Pharmaceutical Samples for Metals Analysis

RSSL

There has been a lot of discussion regarding the methods of analysis for pharmaceutical products as we await the upcoming changes to both the EP and USP, relating to the analysis of metal impurities.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement